Top 2 Health Care Stocks That May Keep You Up At Night This Month

As of September 18, 2025, two healthcare stocks, 89bio Inc (ETNB) and Anteris Technologies Global Corp (AVR), are flagged as overbought with RSIs of 82.2 and 75.9, respectively. Notably, 89bio Inc agreed to be acquired by Roche for $14.50 per share, a 79% premium over its September 17 close, despite its current $8.08 trading price; meanwhile, Anteris Technologies Global, after a 48% monthly gain following mixed quarterly results, closed down 1.8% at $5.61 on Wednesday, indicating potential momentum shifts.

Analysis

Two healthcare sector stocks, 89bio Inc (ETNB) and Anteris Technologies Global Corp (AVR), are exhibiting technically overbought conditions with RSI values of 82.2 and 75.9, respectively. For ETNB, the momentum surge is directly attributable to a definitive M&A event; the company agreed to be acquired by Roche for $14.50 per share in cash. However, with the stock closing at $8.08, there exists a substantial arbitrage gap of approximately 79%, indicating significant market skepticism regarding the deal's certainty, regulatory approval, or timeline to closure. In contrast, AVR's overbought status follows a 48% price appreciation over the past month, which was catalyzed by positive CEO commentary on clinical data for its DurAVR® product, despite the company posting mixed quarterly results. The recent 1.8% decline in AVR's share price to $5.61, coupled with the high RSI, could signal momentum exhaustion and near-term profit-taking by investors.

Key Decisions for Investors

• For 89bio (ETNB), the investment thesis is now a merger arbitrage play; investors should evaluate the probability and timeline of the Roche acquisition closing, as the wide spread between the current price and the $14.50 offer reflects perceived deal risk.
• Regarding Anteris Technologies (AVR), the overbought RSI combined with a recent price drop suggests a heightened risk of a near-term pullback, warranting caution for new long positions and consideration for profit-taking by existing holders.
• Traders should use these high RSI readings not as standalone sell signals, but as prompts to investigate the fundamental catalysts, recognizing the clear distinction between ETNB's M&A-driven momentum and AVR's sentiment-driven rally on clinical progress.